Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).

Bagel, Jerry; Nia, John; Hashim, Peter W; Patekar, Manmath; de Vera, Ana; Hugot, Sophie; Sheng, Kuan; Xia, Summer; Gilloteau, Isabelle; Muscianisi, Elisa; Blauvelt, Andrew; Lebwohl, Mark

Bagel, Jerry; Nia, John; Hashim, Peter W; Patekar, Manmath; de Vera, Ana; Hugot, Sophie; Sheng, Kuan; Xia, Summer; Gilloteau, Isabelle; Muscianisi, Elisa; Blauvelt, Andrew; Lebwohl, Mark.

Afiliação

Bagel J; Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA. dreamacres1@aol.com.
Nia J; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hashim PW; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Patekar M; Novartis Pharma AG, Basel, Switzerland.
de Vera A; Novartis Pharma AG, Basel, Switzerland.
Hugot S; Novartis Pharma AG, Basel, Switzerland.
Sheng K; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Xia S; Novartis Beijing Novartis Pharma Co. Ltd, Shanghai, China.
Gilloteau I; Novartis Pharma AG, Basel, Switzerland.
Muscianisi E; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Blauvelt A; Oregon Medical Research Center, Portland, OR, USA.
Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Dermatol Ther (Heidelb) ; 8(4): 571-579, 2018 Dec.

Article em En | MEDLINE | ID: mdl-30334147

Palavras-chave

Moderate to severe psoriasis; Secukinumab; Ustekinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Dermatol Ther (Heidelb) Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google